Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Regeneron
Regeneron
Regeneron touts possible 'best-in-class' myeloma bispecific, but adverse events climb to 100%
Fierce Biotech
Thu, 12/7/23 - 11:52 am
Regeneron
clinical trials
bispecific
Multiple Myeloma
patient deaths
linvoseltamab
Sanofi, Regeneron eye Dupixent label expansion with promising COPD data
Medical Marketing and Media
Tue, 11/28/23 - 10:27 am
Sanofi
Regeneron
Dupixent
clinical trials
COPD
Regeneron stays out of ADC deal fray as in-house scientists tinker
Fierce Biotech
Wed, 11/15/23 - 11:08 am
Regeneron
antibody-drug conjugate
Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo
Fierce Pharma
Thu, 11/2/23 - 11:48 am
Regeneron
Eylea
Roche
Vabysmo
Regeneron beats quarterly profit estimates on eczema treatment strength
Reuters
Thu, 11/2/23 - 11:33 am
Regeneron
earnings
Dupixent
Dupixent returns as top Rx, OTC brand for September
Medical Marketing and Media
Tue, 10/17/23 - 09:41 pm
Sanofi
Regeneron
Dupixent
DTC ads
pharma ads
Here's the Best Big Pharma Stock of the Decade so Far (and It's Not Even Close)
Motley Fool
Fri, 10/6/23 - 10:05 am
Eli Lilly
Regeneron
Novo Nordisk
Top Pharma Ad Spenders in August 2023, AbbVie Splurges to Take Top Spots
Xtalks
Sun, 10/1/23 - 01:28 pm
pharma advertising
DTC ads
AbbVie
Skyrizi
Rinvoq
Regeneron
Regeneron’s linvoseltamab shows early and durable response in pre-treated MM
Clinical Trials Arena
Fri, 09/29/23 - 11:38 am
Regeneron
clinical trials
bispecific antibodies
linvoseltamab
FDA Decisions 2023: Sandoz, Gilead Sciences and More
BioSpace
Fri, 08/25/23 - 11:31 am
FDA
Sandoz
Novartis
Gilead Sciences
Pfizer
Neurocrine
Regeneron
Ipsen
Revance Therapeutics
Delcath Systems
Janssen
Galera Therapeutics
Biogen
Roche
Mesoblast
Taiho Oncology
Regeneron, J&J Win HHS Funding to Develop Next-Gen COVID Products
BioSpace
Wed, 08/23/23 - 09:54 am
HHS
Regeneron
JNJ
COVID-19
funding
Regeneron Expands Eylea’s Label with High-Dose Approval
BioSpace
Mon, 08/21/23 - 10:44 am
Regeneron
Eylea
FDA
Regeneron’s Antibody Gets FDA Approval for Ultra-Rare Hereditary Disease
BioSpace
Sun, 08/20/23 - 05:17 pm
Regeneron
FDA
CHAPLE disease
Veopoz
FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron
BioSpace
Mon, 08/14/23 - 11:29 am
FDA
Ipsen
Revance Therapeutics
Neurocrine
Regeneron
palovarotene
fibrodysplasia ossificans progressiva
Daxxify
cervical dystonia
Ingrezza
chorea
Huntington's disease
pozelimab
CHAPLE disease
Regeneron's high-dose Eylea shows staying power as company awaits FDA decision
Fierce Pharma
Thu, 08/10/23 - 09:49 pm
Regeneron
Eylea
age-related macular degeneration
FDA
Regeneron adds Decibel to gene therapy playlist, turning up volume on long-running hearing loss collaboration
Fierce Biotech
Wed, 08/9/23 - 10:10 am
Regeneron
hearing loss
Decibel Therapeutics
gene therapy
M&A
Regeneron expects FDA decision on higher-dose Eylea this year
Reuters
Thu, 08/3/23 - 06:40 pm
Regeneron
Eylea
FDA
Moderna, Regeneron post solid earnings, eye a strong finish to 2023
Medical Marketing and Media
Thu, 08/3/23 - 11:23 am
earnings
Moderna Therapeutics
Regeneron
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Fierce Biotech
Thu, 08/3/23 - 10:17 am
Regeneron
prostate cancer
clinical trials
patient deaths
REGN5678
bispecific antibodies
5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year
BioSpace
Fri, 07/28/23 - 11:46 am
Ipsen
palovarotene
fibrodysplasia ossificans progressiva
Regeneron
CHAPLE disease
pozelimab
Biomarin
Voxzogo
achondroplasia
Santhera Pharmaceuticals
vamorolone
DMD
Springworks
nirogacestat
desmoid tumors
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »